MedPAC Wants To Boost Generic Use By Low-Income Part D Enrollees Via Lower Copays
This article was originally published in The Pink Sheet Daily
At its December meeting, the Medicare Payment Advisory Commission recommends that Congress increase the difference between copayments for generic and branded drugs used by low-income beneficiaries to encourage greater generic use in that population.
You may also be interested in...
HHS is expected to move ahead with action to address high drug prices following a series of stakeholder roundtables held over the past month.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.